Kronos Bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. Leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, Kronos utilizes its small molecule microarray (SMM) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/18/19 | $105,000,000 | Series A |
Vida Ventures | undisclosed |
